Esomeprazole News and Research

RSS
Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.
FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN reports revenue of $4.6 million for second quarter 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Watson announces acquisition of Specifar Pharmaceuticals

Watson announces acquisition of Specifar Pharmaceuticals

Dr. Reddy's 2011 consolidated revenues increase 6% to Rs. 74.7 billion

Dr. Reddy's 2011 consolidated revenues increase 6% to Rs. 74.7 billion

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN reports revenue of $4.5 million for first quarter 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

AstraZeneca introduces new CRESTOR and NEXIUM customer service websites

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Broad opportunities for covalent drugs

Broad opportunities for covalent drugs

Dr. Reddy’s third quarter consolidated revenues increase 10% to $424 million

Dr. Reddy’s third quarter consolidated revenues increase 10% to $424 million

Further studies needed over use of Proton-Pump Inhibitors in early pregnancy

Further studies needed over use of Proton-Pump Inhibitors in early pregnancy

VIMOVO granted marketing and pricing approval in the UK

VIMOVO granted marketing and pricing approval in the UK

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Studies explore impact of upper GI conditions on sleep

Studies explore impact of upper GI conditions on sleep

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

POZEN reports $16.2M net income for second-quarter 2010

POZEN reports $16.2M net income for second-quarter 2010